TYRO3P: A Potential Drug Target and Biomarker for Pyruvate Kinase-Driven diseases

Target Name: TYRO3P

NCBI ID: G7302

TYRO3P

Other Name(s): TYRO3P protein tyrosine kinase pseudogene

TYRO3P: A Potential Drug Target and Biomarker for Pyruvate Kinase-Driven diseases

Introduction

Pyruvate kinase (PK) is a critical enzyme involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. In humans, pyruvate kinase has four isoforms, Pyruvate Kinase (PK), Pyruvate Kinase-Activating Subunit (PK-AS), Pyruvate Kinase-Inhibitor (PK-I), and Pyruvate Kinase-Light (PK-L), which are encoded by the genes PKM1, PKM2, PKM3, and PKL, respectively. The Pyruvate Kinase gene (PK) is located on chromosome 16, and it has been implicated in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

The TYRO3P gene, located on chromosome 8, has been identified as a pseudogene that encodes for the protein tyrosine kinase (PK). The protein encoded by the TYRO3P gene is a key regulator of the PK pathway, and it has been involved in the regulation of various cellular processes, including cell growth, differentiation, and metabolism.

Diseases associated with Pyruvate Kinase

Pyruvate kinase has been implicated in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In cancer, PK has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. For example, studies have shown that PK is involved in the regulation of the growth and differentiation of cancer cells, and that it can inhibit the inhibition of cell division by apoptosis.

In neurodegenerative diseases, PK has been implicated in the regulation of neurotransmitter synthesis and release, and it has been shown to play a role in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, studies have shown that PK can regulate the levels of neurotransmitters, such as dopamine and serotonin, and that these levels are affected in neurodegenerative diseases.

In addition to its role in the nervous system, PK has also been implicated in the regulation of metabolism and energy homeostasis. For example, studies have shown that PK can regulate the levels of acetyl-CoA, which is a key substrate for the citric acid cycle , and that this regulation is involved in the pathogenesis of various metabolic disorders, including obesity and type 2 diabetes.

Potential drug targets and biomarkers

The TYRO3P gene has been identified as a potential drug target for the treatment of various diseases associated with Pyruvate Kinase. The following are the potential drug targets and biomarkers associated with TYRO3P:

1. PK inhibitors: PK inhibitors, such as deep interpolation charge (DSP) and alanine aminotransferase (ALT), have been shown to be effective in the treatment of various diseases associated with PK, including cancer and neurodegenerative diseases.

2. PK modulators: PK modulators, such as rapamycin and rapamycin-like drugs, have also been shown to be effective in the treatment of various diseases associated with PK, including cancer and neurodegenerative diseases.

3. PK activators: PK activators, such as

Protein Name: TYRO3P Protein Tyrosine Kinase Pseudogene

The "TYRO3P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TYRO3P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets